ArticleBMC microbiology2025
Genomic and functional characterization of a novel lytic phage vB-AbaM-fThrA with anti-biofilm activity against CR-MDR Acinetobacter baumannii.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant Acinetobacter baumannii causes increasingly fat5al infections in humans. Phage therapy is considered as a promising approach to treat the infections.
methodsHere we present the isolation and characterization of a new lytic A. baumannii specific phage vB-AbaM-fThrA (fThrA for short) originating from hospital wastewater.
resultsPhage fThrA has a myovirus morphology with a relatively broad host range. The phage forms large and transparent plaques with a halo and showed high lysis power in in-vitro laboratory studies. Based on the genome sequence analysis phage fThrA is a new member of the Obolenskvirus genus with about 75.6% genomic similarity to its closest relative. The phage, tolerated well pH range from 4 to 10, and heating at 50 °C, but not 80 °C. At pH 2 ca. 50% of the phage survived for 1 h, an indication that the phage would be suitable for oral administration and phage therapy of the digestive tract. Phage fThrA was highly active against formation of biofilm and in destruction of the formed biofilm, an asset when used as a supplement to antibiotics in severe infections. Also, in genomic studies, no genes related to pathogenicity and lysogenicity were observed in the whole phage sequence.
conclusionsThese features make phage fThrA as a promising candidate for phage therapy in-vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.